Renal transplantation using kidneys from a donor with high grade cytomegalovirus viraemia: case report and literature review.

IF 36.4 1区 医学 Q1 INFECTIOUS DISEASES Lancet Infectious Diseases Pub Date : 2024-11-01 Epub Date: 2024-07-08 DOI:10.1016/S1473-3099(24)00359-1
Kasra Shirini, Shani Kamberi, Cynthia Drachenberg, Abdolreza Haririan, Kapil Saharia, Raphael P H Meier
{"title":"Renal transplantation using kidneys from a donor with high grade cytomegalovirus viraemia: case report and literature review.","authors":"Kasra Shirini, Shani Kamberi, Cynthia Drachenberg, Abdolreza Haririan, Kapil Saharia, Raphael P H Meier","doi":"10.1016/S1473-3099(24)00359-1","DOIUrl":null,"url":null,"abstract":"<p><p>Transplanting organs from cytomegalovirus-seropositive donors into cytomegalovirus-seronegative recipients is an accepted practice. However, outcomes following transplantation of organs from donors with active cytomegalovirus disease are unknown. We present a case involving a patient aged 61 years with end-stage renal disease, seropositive for cytomegalovirus, who underwent dual kidney transplant from a donor with high-grade cytomegalovirus viraemia. The donor was on immunosuppressive therapy for systemic lupus erythematosus and interstitial lung disease and had been admitted with respiratory failure. The donor had high-grade cytomegalovirus viraemia with probable cytomegalovirus pneumonitis (cytomegalovirus viral load >100 000 international units [IU]/mL in plasma and 319 000 IU/mL in bronchoalveolar lavage). Renal biopsy at organ procurement showed the absence of cytomegalovirus inclusions. Following transplantation, the recipient had delayed graft function, with renal recovery after 1 week. The patient received basiliximab induction and standard tacrolimus-based maintenance immunosuppression. He received ganciclovir and valganciclovir treatment for 1 month, followed by valganciclovir prophylaxis (or viral load monitoring, when prophylaxis had to be paused) for 2 additional months to prevent donor-derived cytomegalovirus infection. Transient cytomegalovirus viraemia (peaking at 4480 IU/mL) developed at 4 months and resolved with 1 month of valganciclovir treatment. The patient is doing well 1 year after transplantation, with adequate kidney function. This case highlights the successful and safe transplantation of kidneys from a donor with cytomegalovirus disease into a cytomegalovirus-seropositive recipient. Further research is needed to confirm our findings and define post-transplantation management.</p>","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":" ","pages":"e718-e723"},"PeriodicalIF":36.4000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/S1473-3099(24)00359-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/8 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Transplanting organs from cytomegalovirus-seropositive donors into cytomegalovirus-seronegative recipients is an accepted practice. However, outcomes following transplantation of organs from donors with active cytomegalovirus disease are unknown. We present a case involving a patient aged 61 years with end-stage renal disease, seropositive for cytomegalovirus, who underwent dual kidney transplant from a donor with high-grade cytomegalovirus viraemia. The donor was on immunosuppressive therapy for systemic lupus erythematosus and interstitial lung disease and had been admitted with respiratory failure. The donor had high-grade cytomegalovirus viraemia with probable cytomegalovirus pneumonitis (cytomegalovirus viral load >100 000 international units [IU]/mL in plasma and 319 000 IU/mL in bronchoalveolar lavage). Renal biopsy at organ procurement showed the absence of cytomegalovirus inclusions. Following transplantation, the recipient had delayed graft function, with renal recovery after 1 week. The patient received basiliximab induction and standard tacrolimus-based maintenance immunosuppression. He received ganciclovir and valganciclovir treatment for 1 month, followed by valganciclovir prophylaxis (or viral load monitoring, when prophylaxis had to be paused) for 2 additional months to prevent donor-derived cytomegalovirus infection. Transient cytomegalovirus viraemia (peaking at 4480 IU/mL) developed at 4 months and resolved with 1 month of valganciclovir treatment. The patient is doing well 1 year after transplantation, with adequate kidney function. This case highlights the successful and safe transplantation of kidneys from a donor with cytomegalovirus disease into a cytomegalovirus-seropositive recipient. Further research is needed to confirm our findings and define post-transplantation management.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用巨细胞病毒高度病毒血症捐献者的肾脏进行肾移植:病例报告和文献综述。
将巨细胞病毒血清反应阳性供体的器官移植给巨细胞病毒血清反应阴性的受体是一种公认的做法。然而,巨细胞病毒活动期供体器官移植后的结果尚不清楚。我们介绍了一个病例,患者 61 岁,患有终末期肾病,巨细胞病毒血清反应呈阳性,接受了巨细胞病毒高度病毒血症供体的双肾移植。供体因系统性红斑狼疮和间质性肺病接受免疫抑制治疗,入院时出现呼吸衰竭。供体患有巨细胞病毒血症,可能患有巨细胞病毒性肺炎(血浆中巨细胞病毒载量大于 100 000 国际单位 [IU]/毫升,支气管肺泡灌洗液中病毒载量大于 319 000 国际单位/毫升)。器官采购时进行的肾活检显示没有巨细胞病毒包涵体。移植后,受者移植功能延迟,1 周后肾功能恢复。患者接受了巴利昔单抗诱导治疗和基于他克莫司的标准维持性免疫抑制治疗。他接受了为期 1 个月的更昔洛韦和缬更昔洛韦治疗,随后又接受了为期 2 个月的缬更昔洛韦预防(或病毒载量监测,当预防不得不暂停时),以防止供体源性巨细胞病毒感染。4 个月时出现一过性巨细胞病毒病毒血症(峰值为 4480 IU/mL),经过 1 个月的缬更昔洛韦治疗后缓解。移植手术 1 年后,患者恢复良好,肾功能正常。本病例强调了将患有巨细胞病毒病的供体的肾脏成功、安全地移植给巨细胞病毒血清阳性受体。我们需要进一步的研究来证实我们的发现并确定移植后的管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Lancet Infectious Diseases
Lancet Infectious Diseases 医学-传染病学
CiteScore
60.90
自引率
0.70%
发文量
1064
审稿时长
6-12 weeks
期刊介绍: The Lancet Infectious Diseases was launched in August, 2001, and is a lively monthly journal of original research, review, opinion, and news covering international issues relevant to clinical infectious diseases specialists worldwide.The infectious diseases journal aims to be a world-leading publication, featuring original research that advocates change or sheds light on clinical practices related to infectious diseases. The journal prioritizes articles with the potential to impact clinical practice or influence perspectives. Content covers a wide range of topics, including anti-infective therapy and immunization, bacterial, viral, fungal, and parasitic infections, emerging infectious diseases, HIV/AIDS, malaria, tuberculosis, mycobacterial infections, infection control, infectious diseases epidemiology, neglected tropical diseases, and travel medicine. Informative reviews on any subject linked to infectious diseases and human health are also welcomed.
期刊最新文献
Pui-Ying Iroh Tam Research in brief Justyna Kowalska—reaching underserved people with HIV Subretinal and brain abscesses caused by Streptococcus intermedius Clinical trials versus the real world in tuberculosis control
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1